Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06592170 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)

Name: Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL) — clinical trial record (NCT06592170)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MZL-001

StatusRecruiting

PhasePhase 1/2

SponsorThe First Hospital of Jilin University

Started2024-08-13

View on ClinicalTrials.gov ↗

Record status

This record was last updated September 19, 2024 (before its estimated August 13, 2025 completion). Its status may not reflect the trial's current state.

The First Hospital of Jilin University

86 trials monitored

See 2 trials at risk

This is a single arm, open label, national multicenter clinical study included patients with marginal zone lymphoma patients (MZL) , aim is to evaluate the efficacy and safety of first-line treatment with Linperlisib combined with obinutuzumab in patients with marginal zone lymphoma (MZL).

Trial Details

NCT Number	NCT06592170
Lead Sponsor	The First Hospital of Jilin University
Conditions	Lymphoma
Enrollment	35 participants
Start Date	2024-08-13
Primary Completion	2025-08-13 (estimated)
Study Completion	2027-08-13 (estimated)
Updated on ClinicalTrials.gov	2024-09-19